Treatment of Limited-Stage, Non-Bulky Angioimmunoblastic T-cell Lymphoma with a Favourable Pretherapeutic Risk Profile

This protocol addresses first-line management of angioimmunoblastic T-cell lymphoma in a specific, well-defined clinical subset: limited stage, non-bulky disease, and a favourable pretherapeutic risk profile — a combination that shapes the intensity and sequence of treatment.

Patients in this group present with angioimmunoblastic T-cell lymphoma that is limited in stage and without bulky tumour burden. The pre-treatment risk assessment is favourable. This profile distinguishes them from advanced-stage or high-risk presentations and supports a tailored first-line strategy that differs from the more intensive approaches used in other settings.

For this scenario, the structured approach begins with an abbreviated course of first-line chemotherapy. Patients whose disease responds may then be considered for consolidative involved-site radiotherapy as the next step — the complete regimen, sequencing criteria, and evidence grading are in the full protocol.